(Q36238870)

13 August 2017

1 reference

title

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma (English)

1 reference

13 August 2017

3

Laura Rosiñol

1 reference

13 August 2017

Joan Bladé

1

1 reference

13 August 2017

M Teresa Cibeira

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

44

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

440-448

1 reference

Involvement of the proteasome in various degradative processes in mammalian cells.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

The proteasome: a proteolytic nanomachine of cell regulation and waste disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Proteasome inhibitors as therapeutic agents: current and future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Gene therapy for inherited disorders of haematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

A mouse model for visualization and conditional mutations in the erythroid lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

Bortezomib-induced severe hepatitis in multiple myeloma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860510030002

10.1080/02841860510030002

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference